LIQ861

June 7, 2019June 7, 2019

Liquidia Moves Closer to Requesting FDA Approval of LIQ861 for PAH

News, PAH News

The latest INSPIRE Phase 3 trial data on LIQ861 as a treatment for pulmonary arterial hypertension (PAH) support the submission of a New Drug Application (NDA) with the U.S. ... Read more

March 14, 2019March 19, 2019

Liquidia’s LIQ861 Safe and Effective in PAH Patients, Phase 3 Trial Suggests

News, PAH News

A Phase 3 clinical trial testing LIQ861 met its primary objective, showing that the investigational inhaled dry powder treprostinil formulation is safe and effective for the treatment of pulmonary arterial hypertension (PAH), according ... Read more

November 2, 2018November 9, 2018

Liquidia Completes Enrollment for Safety Portion of Phase 3 Trial on LIQ861 for PAH

News, PAH News

Liquidia Technologies has completed the enrollment for the safety part of a Phase 3 trial evaluating the safety and tolerability of LIQ861, an inhaled dry power formulation of treprostinil for the ... Read more

January 26, 2018January 26, 2018

Phase 1 Trial Results Support Powder Formulation of Treprostinil Advancing to Phase 3 Studies, Liquidia Says

News, PAH News

Results of a Phase 1 clinical trial of Liquidia Technologies’ powder formulation of treprostinil for pulmonary hypertension were promising enough to advance it into Phase 3 trials, the company reports. ... Read more

January 9, 2018January 9, 2018

Liquidia Starts Phase 3 Clinical Trial of Pulmonary Hypertension Treatment

News, PAH News

Liquidia Technologies has started a Phase 3 clinical trial to evaluate LIQ861 as a treatment for pulmonary arterial hypertension. LIQ861 is a dry-powder, inhaled formulation of treprostinil that Liquidia developed to ... Read more

Pin It on Pinterest